p38δ knockdown in CRC lines also demonstrated anti-proliferative effects; however, as presently, p38δ specific inhibitors do not exist, it has been proposed that MKK3 inhibitors may be a potential treatment for colorectal cancer owing to the inhibition of MKK3/p38δ prosurvival signaling [89,90]. This evidence concerns the gene MAP2K3 and colorectal carcinoma.